Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023–January 2024

Publié le 5 juin 2024 Mis à jour le 7 février 2025

In September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case–control study based on the test-negative design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5–88.7) in the main analysis and 80.6% (61.6–90.3) and 80.4% (61.7–89.9) in two sensitivity analyses. These real-world estimates confirmed the efficacy observed in clinical studies.

Auteur(s) : Paireau Juliette, Durand Cécile, Raimbault Sylvain, Cazaubon Joséphine, Mortamet Guillaume, Viriot Delphine, Milesi Christophe, Daudens-Vaysse Elise, Ploin Dominique, Tessier Sabrina, Vanel Noémie, Chappert Jean-Loup, Levieux Karine, Ollivier Ronan, Daoudi Jamel, Coignard Bruno, Leteurtre Stéphane, Parent-du-Châtelet Isabelle, Vaux Sophie

Année de publication : 2024

Pages : e13311